Business Wire

A new mobility ecosystem will personalize every journey by 2030

27.4.2023 09:35:00 EEST | Business Wire | Press release

Share

Management and technology consultancy BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. The study, Mobility 2030, says all players will battle over customer and value chain data, and service offerings must address national as well as urban and rural demand patterns.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005716/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. (Graphic: Business Wire)

“The automotive industry must respond to the human-centric mobility trend to stay ahead of the competition by maintaining its strategic position as the prime touchpoint to the customer. The industry must provide customers with truly personalized offerings, focus on collecting complex data to derive actionable insights, and orchestrate an ecosystem of partners that embraces new technologies,” said Dr. Stefan Penthin, Global Leader Automotive and Industrial Manufacturing at BearingPoint.

The study is the first in a series of three on mobility and drew from BearingPoint’s internal research, the views of clients across all industry segments and input from the consultancy’s segment and technology leaders. While the automotive industry is the focus, the study examines how all segments will be active in the new mobility ecosystem, from manufacturers and transportation providers to energy suppliers, government organizations, and insurance companies.

By 2030, the study projects that approximately 23% of all megacity trips will be through shared, on-demand mobility offerings (up from just 8% in 2021). By 2030, each player will be part of a demanding new infrastructure and alliance-ecosystem relationships that deliver multimodal journeys with diverse powertrains. Mobility will be consumed as a service, so access to data will be key. On-demand services mean all players will compete to acquire, analyze, and exploit customer data so they can react to changing travel patterns.

“In the journey to 2030, the transportation experience will become individualized, and new infrastructure, services, and relationships will be needed. Providers must be more user-centered and cater to rural and urban demands. Ultimately both utility companies and public transportation organizations will have a new and larger role,” said Marion Schulte, Global Leader Utilities, Postal and Transportation at BearingPoint.

Mobility that maximizes security, personal well-being, and sustainability

Various modes of travel will become integrated, enabling urban and rural intermodal transport hubs. Customers will demand mobility that maximizes security, personal well-being, and sustainability. Risk profiles will diverge for different usage and regions, the study foresees. According to EU statistics, 17 of the 20 busiest air routes in Europe cover distances of less than 434 miles, distances where intercity trains can offer faster, cleaner, and more sustainable journeys.

“As citizens demand greater availability, quality, and flexibility from mobility services, public transportation policy will evolve. Governments should ensure equal access to transport networks for all citizens, and the various modes of travel must be carefully integrated with safety, security, and personal well-being key priorities. Mobility policies should also be designed to maximize citizens productivity, both in terms of working and non-working time,” said Andrew Montgomery, Global Leader Government and Public Sector.

For more details and insights, you can download the study here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030-what-happens-when-every-journey-is-personalized/

About BearingPoint

BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.

BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.

For more information, please visit:

Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye